Search Results - "Frey, Steve"

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis by Simpson, Eric, Bissonnette, Robert, Eichenfield, Lawrence F., Guttman-Yassky, Emma, King, Brett, Silverberg, Jonathan I., Beck, Lisa A., Bieber, Thomas, Reich, Kristian, Kabashima, Kenji, Seyger, Marieke, Siegfried, Elaine, Stingl, Georg, Feldman, Steven R., Menter, Alan, van de Kerkhof, Peter, Yosipovitch, Gil, Paul, Carle, Martel, Philippe, Dubost-Brama, Ariane, Armstrong, John, Chavda, Rajeev, Frey, Steve, Joubert, Yolandi, Milutinovic, Marina, Parneix, Anne, Teixeira, Henrique D., Lin, Chen-Yen, Sun, Luna, Klekotka, Paul, Nickoloff, Brian, Dutronc, Yves, Mallbris, Lotus, Janes, Jonathan M., DeLozier, Amy M., Nunes, Fabio P., Paller, Amy S.

“…An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack…”
Get full text

Structural and Functional Definition of the Human Chitinase Chitin-binding Domain by Tjoelker, L W, Gosting, L, Frey, S, Hunter, C L, Trong, H L, Steiner, B, Brammer, H, Gray, P W

“…Mammalian chitinase, a chitinolytic enzyme expressed by macrophages, has been detected in atherosclerotic plaques and is elevated in blood and tissues of…”
Get full text

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors by Yap, Timothy A, Winter, Jane N, Giulino-Roth, Lisa, Longley, Jemma, Lopez, Juanita, Michot, Jean-Marie, Leonard, John P, Ribrag, Vincent, McCabe, Michael T, Creasy, Caretha L, Stern, Melissa, Pene Dumitrescu, Teodora, Wang, Xiaowei, Frey, Steve, Carver, Jennifer, Horner, Thierry, Oh, Choon, Khaled, Ahmed, Dhar, Arindam, Johnson, Peter W M

“…Enhancer of zeste homolog 2 (EZH2) activity is dysregulated in many cancers. This phase I study determined the safety, maximum-tolerated dose (MTD),…”
Get full text

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM) by Nooka, Ajay K., Stockerl-Goldstein, Keith, Quach, Hang, Forbes, Adam, Mateos, Maria-Victoria, Khot, Amit, Tan, Alan, Abonour, Rafat, Chopra, Bikramjit, Rogers, Rachel, Ferron-Brady, Geraldine, Davidge, Jacqueline, Frey, Steve, Yeakey, Anne, Talekar, Mala, Luptakova, Katarina, Gupta, Ira, Popat, Rakesh

“…Abstract only 8502 Background: Belantamab mafodotin, a B-cell maturation antigen targeting immunoconjugate, demonstrated clinically meaningful, single-agent…”
Get full text

In vivo characterization of minipig skin as a model for dermatological research using multiphoton microscopy by Alex, Aneesh, Chaney, Eric J., Žurauskas, Mantas, Criley, Jennifer M., Spillman, Darold R., Hutchison, Phaedra B., Li, Joanne, Marjanovic, Marina, Frey, Steve, Arp, Zane, Boppart, Stephen A.

“…Minipig skin is one of the most widely used non‐rodent animal skin models for dermatological research. A thorough characterization of minipig skin is essential…”
Get full text

Recombinant human antibodies to IFN-α from the immune repertoires of MG/thymoma donors (83.13) by Hammond, Philip, Boozer, Christy, Branum, Mark, Fox, Raymond, Lilly, Rebecca, Mosley, Bruce, Ward, Courtney, Whitman, Darbie, Frey, Steve, Cicirelli, Mike, Olsen, Ole, Moyle, Matthew

“…Abstract A serum titer of autoantibodies to IFN-α has been reported in several autoimmune conditions and in many cases has been shown to neutralize IFN-α. The…”
Get full text

Isolation of A Human GM-CSF Antibody with Potent Neutralizing Activity from a Subject with Idiopathic Pulmonary Alveolar Proteinosis (96.24) by Chan-hui, Po-Ying, Cox, Tom, Grondin, Roxanne, Grandea, Glen, Frey, Steve, Branum, Mark, Ward, Courtney, Fox, Ray, Olsen, Ole, Hammond, Phil, Cieplak, Witold, Moyle, Matthew

“…Abstract Background. GM-CSF has been implicated in the development of autoimmune disorders. The efficacy of neutralizing anti-GM-CSF has been demonstrated in…”
Get full text

A strategy to identify human monoclonal antibodies that neutralize a broad spectrum of influenza A subtypes (38.12) by Olsen, Ole, Frey, Steve, Boozer, Christy, Grandea, Glen, Cicarelli, Mike, Lily, Rebecca, Ward, Courtney, Fitch, Alison, Feng, I-wei, Jellyman, David, Grondin, Roxanne, Gibbs, Aaron, Chan-hui, Po-ying, Whitman, Darbie, Fox, Ray, Mosley, Bruce, Hammond, Phil, Branum, Mark, Cieplak, Witold, Moyle, Matthew

“…Abstract Influenza A continues to be a serious public health threat as it continuously evolves to evade and escape immune surveillance through genetic drift,…”
Get full text

Inactivated whole-cell bacterial vaccines: current status and novel strategies by Pace, John L., Rossi, Humberto A., Esposito, Vito M., Frey, Steve M., Tucker, Kenneth D., Walker, Richard I.

“…Inactivated bacterial whole-cell vaccines have been the most widely studied prophylactic treatment for infectious diseases. They offer an economical, and…”
Get full text

More pleas for Pluto by Miller, Charlie, Brescia, Keith, Bjornstad, David M, Frey, Steve, Weissman, Paul

Get full text